Integral Molecular is a research-driven biotechnology company creating innovative technologies and therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes.

June 1, 2018

Integral Molecular Celebrates Epitope Mapping Milestone of 1,000 Epitopes

PHILADELPHIA-(BUSINESS WIRE)-Integral Molecular, the industry leader in the discovery and characterization of antibodies against membrane proteins, celebrates a milestone of mapping 1,000 epitopes for customers, collaborators, […]
May 30, 2018

Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

Integral Molecular, the industry leader in membrane protein antibody discovery, announces the development of antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic […]
March 13, 2018

Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development

PHILADELPHIA–(BUSINESS WIRE)-Integral Molecular, the industry leader in engineering membrane proteins, has extended its protein engineering capabilities to stabilize viral proteins and produce more effective candidate vaccines […]
December 21, 2017

Integral Molecular Expands its Epitope Mapping Platform to Identify Small Molecule Binding Sites on Multipass Membrane Proteins

PHILADELPHIA–(BUSINESS WIRE)– Integral Molecular, the industry leader in the expression and characterization of multipass membrane proteins, has expanded its mapping capabilities to include small molecules. This […]
September 6, 2017

Integral Molecular Hosts Art of Science Residency

PHILADELPHIA (September 6, 2017) – A new kind of interdisciplinary artistic collaboration is happening in Philadelphia this fall. The University City Science Center has partnered with […]
August 30, 2017

Integral Molecular Doubles Antibody Discovery Capacity

PHILADELPHIA-(BUSINESS WIRE)-Integral Molecular, a Philadelphia based biotechnology company, announces the expansion of its facility, personnel, and resources dedicated to antibody discovery for membrane protein targets. The […]
June 15, 2017

Integral Molecular Announces Technology Advancement for Discovery of New Immuno-Oncology Therapeutic Targets

PHILADELPHIA-(BUSINESS WIRE)-Integral Molecular, a leader in membrane protein technologies, has initiated a therapeutic target discovery program in immuno-oncology by exploiting its Membrane Proteome Array technology to […]
June 7, 2017

Integral Molecular Announces the Expansion of its Membrane Proteome Array Technology for Improving Antibody Safety and New Target Discovery

PHILADELPHIA–Integral Molecular announces the expansion of its proprietary Membrane Proteome Array™ to now consist of 5,300 unique human membrane proteins, representing nearly the entire human membrane […]
May 18, 2017

Immunization Elicited Antibody Shows Universal Protection Against Multiple Ebolaviruses

ROCKVILLE, Md., May 18, 2017 /PRNewswire/ — In research published online today in Cell, a team of scientists describe an antibody called CA45, elicited by immunization […]
March 2, 2017

Integral Molecular and Integrated BioTherapeutics Initiate Collaboration for Virus Vaccine Discovery

Philadelphia, PA & Rockville, MD. (BUSINESSWIRE) March 2, 2017 —Integral Molecular and Integrated BioTherapeutics have teamed up in the fight against the global health crises posed […]
November 16, 2016

Integral Molecular Isolates Zika-Specific Monoclonal Antibodies for Vaccine Research and Diagnostics

PHILADELPHIA — Integral Molecular announces the isolation of neutralizing monoclonal antibodies specific for the Zika virus envelope, thereby enabling vital vaccine research and the development of […]
November 7, 2016

Antibody Protects Against Fetal Disease in Mouse Model of Zika Infection

Administering a human antibody that neutralizes Zika virus to pregnant mice before or after Zika virus infection reduced levels of the virus in placental and fetal […]
September 21, 2016

Integral Molecular Launches Target Specificity Technology to Improve Safety of Biotherapeutics

Integral Molecular announces the launch of the Membrane Proteome Array (MPA), a rapid and reliable platform for de-risking therapeutic development by profiling the target specificity of […]
August 25, 2016

Integral Molecular Announces Breakthrough in Understanding the Functionality of GPCRs, the Largest Class of Drug Targets in Human Disease

Philadelphia, PA–(BUSINESS WIRE)–Integral Molecular, an industry leader in membrane protein antibody discovery, has announced a major advancement in understanding the functionality of G protein-coupled receptors (GPCRs), […]
May 26, 2016

Integral Molecular Develops B-Cell Cloning Technology to Discover Rare Antibodies against Membrane Proteins

Integral Molecular, a leader in antibody discovery, announces the development of an ultra high-throughput microfluidic B-cell cloning technology that can interrogate tens of millions of immune […]
February 10, 2016

Integral Molecular Expands Intellectual Property Landscape with International Patents Protecting Key Lipoparticle technology

Integral Molecular, a leader in membrane protein antibody discovery, has announced the issuance of two key patents in Europe and the U.S., strengthening the company’s rapidly […]
December 11, 2015

DNA Immunization Expert Dr. Ross Chambers Joins Integral Molecular to Lead Antibody Discovery

Integral Molecular, a leader in membrane protein antibody discovery, announced today the appointment of DNA immunization expert Ross Chambers, Ph.D., as Director of Antibody Discovery. Dr. […]
November 12, 2015

Integral Molecular Identifies Key Molecular Interactions Responsible for the Effectiveness of the ZMapp™ Anti-Ebola Virus Cocktail

To support the creation of Ebola virus vaccines and treatments, Integral Molecular, a leader in membrane protein antibody discovery, has identified the key molecular interactions that […]
October 15, 2015

Integral Molecular Awarded $5.5M by the National Institutes of Health to Study Ebola Antibodies to Aid in Vaccine Discovery

With a new $5.5M award from the National Institute of Allergy and Infectious Diseases (NIAID) part of the National Institutes of Health (NIH), Integral Molecular, Inc. […]
July 3, 2015

Cat Got Your Tongue? Not According to New Research

The ability to detect bitter chemicals is thought to have evolved because it helps animals avoid toxic compounds often found in plants. All cats, from pets […]